SanguiBioTech yields revenues of around USD42,000 in Q4 2014 according to preliminary figures
Business Wire - Tue Jul 29, 10:50AM CDT
According to preliminary, unaudited figures Sangui Biotech International, Inc. yielded revenues from royalties and product sales of USD42,000 in the course of the fourth quarter of its financial year 2014, ended June 30, 2014. In the third quarter (ended March 31, 2014) revenues had amounted to USD29,438; in the fourth quarter of its financial year 2013 (ended June 30, 2013) the company reported revenues of USD24,056. Based on this preliminary state of accounting Sangui will presumably present revenues of more than USD130,000 for its 2014 financial year (FY 2013: USD105,487).
Biotech Enterprise Sangui Starts Expanding Internationally Recording Large Order From Mexico
PR Newswire - Fri Dec 21, 7:00AM CST
Effective now, Sangui BioTech International, Inc. (Symbol: SGBI ) has its wound therapeutic Granulox being sold in Mexico. Sangui BioTech GmbH has licensed the respective rights to its affiliate SastoMed GmbH. SastoMed is already distributing Granulox in Germany. At the outset of the international expansion a large order could be recorded yielding an expected sales volume of over EUR500,000.